Von Willebrand Disease Clinical Trial
Official title:
Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.
Inherited von Willebrand disease (VWD) is considered the most common bleeding disorder. Its prevalence is approximately 1% in the general population but symptomatic patients are rarer (0.01%). It is caused by a partial or total quantitative deficiency (type 1 and type 3) or by a qualitative defect (type 2) of von Willebrand factor (VWF), a large multimeric protein that is required for platelet adhesion and serves as factor VIII (FVIII) carrier. Type 2 VWD is further divided in four subgroups (2A, 2B, 2M, and 2N) that are distinguished according to the nature of the VWF defect. Most patients with type 1 VWD can be treated with the synthetic vasopressin analogue desmopressin (DDAVP; 2-desamino-8-D-arginine vasopressin), whereas patients with type 3 VWD and most patients with type 2 VWD require concentrates containing VWF. Plasma-derived FVIII concentrates, which were initially developed for the treatment of haemophilia, contain large amounts of VWF and are used in patients for whom DDAVP treatment is deemed ineffective or contraindicated. Voncento® (CSL Behring) is a plasma-derived FVIII/VWF concentrate registered in France since 2015 for the treatment and prevention of bleeding events in patients with inherited VWD. OPALE is an observational study describing the use of human coagulation FVIII/VWF concentrate (Voncento®) to treat and prevent bleeding episodes in a French cohort of patients with inherited von Willebrand disease in the real life settings. The aim of the OPALE study is to describe the efficacy and the safety of Voncento® in the prophylaxis and treatment of haemorrhage or surgical bleeding. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01651468 -
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
|
N/A | |
| Active, not recruiting |
NCT00555555 -
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
|
Phase 4 | |
| Terminated |
NCT00178542 -
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
|
N/A | |
| Completed |
NCT02552576 -
Study of Voncento® in Subjects With Von Willebrand Disease
|
Phase 4 | |
| Recruiting |
NCT02869074 -
Molecular and Clinical Profile of Von Willebrand Disease in Spain
|
||
| Completed |
NCT01602419 -
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|
||
| Completed |
NCT01224808 -
Extension Study of Biostate in Subjects With Von Willebrand Disease
|
Phase 3 | |
| Completed |
NCT00805051 -
Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
|
N/A | |
| Withdrawn |
NCT00694785 -
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
|
Phase 2 | |
| Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
| Completed |
NCT02246881 -
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
|
Phase 3 | |
| Withdrawn |
NCT00630448 -
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
|
N/A | |
| Terminated |
NCT00387192 -
A Study With OPTIVATE® in People With Von Willebrand Disease
|
Phase 3 | |
| Completed |
NCT02973087 -
rVWF IN PROPHYLAXIS
|
Phase 3 | |
| Completed |
NCT01410227 -
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
|
Phase 3 | |
| Completed |
NCT01949220 -
Willebrand International Non-interventional Global Surveillance
|
||
| Completed |
NCT01589848 -
Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
|
N/A | |
| Completed |
NCT00941616 -
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00557908 -
The Von Willebrand Disease (VWD) International Prophylaxis Study
|
N/A | |
| Active, not recruiting |
NCT04953884 -
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
|
Phase 3 |